Cell Reports Medicine · 2023 · 18 citations · 41 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOncology PharmacotherapyBiomarker-guided Therapy SelectionCancer BiomarkersCancer Precision MedicineLung CancerMalignant NeoplasmsTherapy Response AssessmentAmplificationCirculating Tumor Dna TestingHigh-level AmplificationLiquid Biopsy DetectionNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentRb1 AlterationsTherapy Response Evaluation
High-level MET amplification (METamp) is a primary driver in ∼1%-2% of non-small cell lung cancers (NSCLCs). Cohort B of the phase 2 VISION trial evaluates tepotinib, an oral MET inhibitor, in patients with advanced NSCLC with high-level METamp who were enrolled by liquid biopsy. While the study was halted before the enrollment of the planned 60 patients, the results of 24 enrolled patients are presented here. The objective response rate (ORR) is 41.7% (95% confidence interval [CI], 22.1-63.4), and the median duration of response is 14.3 months (95% CI, 2.8-not estimable). In exploratory biomarker analyses, focal METamp, RB1 wild-type, MYC diploidy, low circulating tumor DNA (ctDNA) burden at baseline, and early molecular response are associated with better outcomes. Adverse events include edema (composite term; any grade: 58.3%; grade 3: 12.5%) and constipation (any grade: 41.7%; grade 3: 4.2%). Tepotinib provides antitumor activity in high-level METamp NSCLC (ClinicalTrials.gov: NCT02864992).
41
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
Paul K. Paik, Enriqueta Felip, Rémi Veillon et al. · New England Journal of Medicine · 2020 · 854 citations · Full text
Medicine, Oncology, Pharmacology +15